Imatinib Krka D.D.

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and other BCR‑ABL driven cancers in adult patients.

GNH USA supplies Imatinib Krka D.D. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a targeted therapy that interferes with the BCR‑ABL tyrosine‑kinase pathway and related oncogenic drivers. - Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): facilitates remission through kinase blockade. - Gastrointestinal stromal tumor (GIST): induces tumor shrinkage by targeting KIT/PDGFRA mutations. - Other KIT or PDGFRA driven tumors: helps stabilize disease progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Muscle cramps: occasional painful contractions. - Diarrhea: loose stools. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: reduced left‑ventricular ejection fraction. - Severe neutropenia: marked decrease in white blood cells. - Hemorrhagic events: unusual bleeding or bruising.

Patients should be monitored for organ function and potential toxicities. - Baseline labs: obtain liver, renal, and hematologic parameters before starting therapy. - Cardiac assessment: evaluate cardiac function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Imatinib may alter the pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): can affect absorption. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - CYP2C8 substrates (e.g., repaglinide): potential increased plasma concentrations. - Vaccines: live attenuated vaccines should be avoided during treatment.